Immix Biopharma Investor Presentation Deck slide image

Immix Biopharma Investor Presentation Deck

Broad Autoimmune Disease Applicability of the ImmixBio N-GENIUS Platform Overcoming Neurotoxicity Enables Indication Expansion For NXC-201 CD19 CD20 ● ● ● BCMA Myasthenia Gravis Neuromyelitis Optica Spectrum Disorder Multiple Sclerosis Pemphigus Vulgaris Ulcerative Colitis Bone Marrow Pro-B Pre-B Immature B Naïve B Neurology Dermatology Gastroenterology Periphery Bone MarrowI I I GC B Memory B Plasma blast Plasma cell I I I I I Rheumatology Hematology Other diseases AL Amyloidosis, Multiple Myeloma (3-days hospital instead of 14-days) Overcoming neurotoxicity ● ● ● ● ● e ●●● S IMMIX BIOPHARMA Systemic Lupus Erythematosus Rheumatoid Arthritis Sjögren Disease Polymyositis Ankylosing Spondylitis AL Amyloidosis Behcet's disease Autoimmune Hemolytic Anemia Pure Red Cell Aplasia Immune Thrombocytopenic Purpura *Illustrative list of autoimmune diseases where B cells may play a role in initiating or maintaining disease, and where NXC-201 may provide a potential treatment Source: Medic Tests. Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 2020. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Qin C, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023. Granit V, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023. Shaker OG, et al. Expression of TNF-a, APRIL and BCMA in Behcet's disease. J Immunol Res. 2014. Shimanovsky A, et al. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016. McGlothlin J, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol. 2023. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? [published correction appears in Nephrol Dial Transplant. 2005. Yu TS, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021. Greenberg SA, et al. Plasma cells in muscle in inclusion body myositis and polymyositis [published correction appears in Neurology. 2006. Wilbrink R, et al. B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. Int J Mol Sci. 2021. Uzzan M, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?. Front Immunol. 2023 6
View entire presentation